Page last updated: 2024-08-17

quinoxalines and ADDH

quinoxalines has been researched along with ADDH in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fraser, K1
Cocores, JA; Gold, MS1
Furberg, CD; Glenmullen, J; Moore, TJ1
Moorman, KL; Whitley, HP1
de Villiers, AS; Jaffer, A; Russell, VA; Sagvolden, T; Searson, A; Taljaard, JJ1
Allie, S; Russell, V; Wiggins, T1

Other Studies

6 other study(ies) available for quinoxalines and ADDH

ArticleYear
72nd annual meeting of the American Academy of Dermatology.
    American journal of clinical dermatology, 2014, Volume: 15, Issue:2

    Topics: Antifungal Agents; Attention Deficit Disorder with Hyperactivity; Boron Compounds; Botulinum Toxins, Type A; Bridged Bicyclo Compounds, Heterocyclic; Brimonidine Tartrate; Depression; Dermatitis, Atopic; Food Hypersensitivity; Humans; Immunologic Factors; Ivermectin; Phosphodiesterase Inhibitors; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinoxalines; Skin Diseases; Societies, Medical; Thalidomide; Triazoles; United States

2014
Varenicline and adult ADHD.
    The Journal of neuropsychiatry and clinical neurosciences, 2008,Fall, Volume: 20, Issue:4

    Topics: Adult; Attention Deficit Disorder with Hyperactivity; Benzazepines; Female; Humans; Nicotinic Antagonists; Psychiatric Status Rating Scales; Quinoxalines; Varenicline

2008
Prescription drugs associated with reports of violence towards others.
    PloS one, 2010, Dec-15, Volume: 5, Issue:12

    Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzazepines; Humans; Hypnotics and Sedatives; Outcome Assessment, Health Care; Pharmaceutical Preparations; Prescription Drugs; Prospective Studies; Quinoxalines; United States; United States Food and Drug Administration; Varenicline; Violence

2010
Interference with smoking-cessation effects of varenicline after administration of immediate-release amphetamine-dextroamphetamine.
    Pharmacotherapy, 2007, Volume: 27, Issue:10

    Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Benzazepines; Central Nervous System Stimulants; Dextroamphetamine; Drug Combinations; Drug Interactions; Humans; Male; Quinoxalines; Recurrence; Smoking; Smoking Cessation; Time Factors; Treatment Outcome; Varenicline

2007
Alpha 2-adrenoceptor mediated inhibition of [3H]dopamine release from nucleus accumbens slices and monoamine levels in a rat model for attention-deficit hyperactivity disorder.
    Neurochemical research, 1995, Volume: 20, Issue:4

    Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antihypertensive Agents; Attention Deficit Disorder with Hyperactivity; Biogenic Monoamines; Brimonidine Tartrate; Disease Models, Animal; Dopamine; Hypertension; In Vitro Techniques; Male; Neurons; Norepinephrine; Nucleus Accumbens; Quinoxalines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Adrenergic, alpha-2; Tritium

1995
Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder--the spontaneously hypertensive rat.
    Behavioural brain research, 2000, Dec-20, Volume: 117, Issue:1-2

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Brimonidine Tartrate; Disease Models, Animal; Dopamine; Down-Regulation; Hypertension; Idazoxan; In Vitro Techniques; Male; Models, Neurological; Norepinephrine; Prefrontal Cortex; Quinoxalines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Long-Evans; Receptors, Adrenergic, alpha-2

2000